Pretreatment inflammation and coagulation biomarkers are associated with increased risk for these important complications after initiation of antiretroviral therapy.
HIV infection accelerates the progression of liver disease in patients coinfected with hepatitis C virus (HCV) or hepatitis B virus (HBV). The risk for hepatitis flare after initiation of antiretroviral therapy (ART) is higher in coinfected patients than in HIV-monoinfected patients. In a recent retrospective cohort study, researchers examined a variety of pre-ART inflammation- and coagulation-related biomarkers to determine whether they might be predictive of hepatitis flare or mortality.
The study involved 287 HIV-infected patients (207 coinfected with HCV, 70 with HBV, and 10 with both HCV and HBV) who participated in a randomized trial of different ART regimens (FIRST). The main outcomes were hepatitis flare within 4 months — or death wi…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)